Howard A. Burris - Concepedia

Author

Howard A. Burris

Also Known As

Burris, H., Burris, Howard, H A Burris, H A Burris III, H Burris, H Burris III, H. A. BURRIS, H. A. Burris, H. A. Burris III, H. BURRIS

1.1K

Publications

71K

Citations

116

H-Index

170

Concepts

All Affiliations

Sarah Cannon Tennessee Oncology The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute

About

Howard A. Burris is an author at Sarah Cannon specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	70	310	27.4K
2	Health Sciences	28	51	4.2K
3	Natural Sciences	2	2	70
4	Law	1	1	22
5	Nursing	1	1	84

Howard A. Burris

519

Publications

67.5K

Citations

113

H-Index

Page 1

	Year	Citations
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, Journal of Clinical Oncology	1997	5.8K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer José Baselga, Mario Campone, Martine Piccart, New England Journal of Medicine	2011	2.8K
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Thomas Powles, Joseph P. Eder, Gregg Fine, Nature UrologyOncologyGenitourinary CancerMedicineCancer Treatment	2014	2.4K
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Paul M. Ridker, Jean MacFadyen, Tom Thurén, The Lancet InflammationAllergyLung InflammationMedicineMetronomic Therapy	2017	1.3K
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer Chris Twelves, A. Wong, Marek P. Nowacki, New England Journal of Medicine	2005	1.2K
Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Journal of Clinical Oncology	2007	1.1K
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, NEJM Evidence Placebo MonotherapyHealth SciencesGastrointestinal OncologyMedicineCancer Management	2022	986

Page 1